University of Iowa Hospitals and Clinics
Phase III trial of enzalutamide (NSC # 766085) versus enzalutamide, abiraterone and prednisone for castration resistant metastatic prostate cancer
Participants in this study have been diagnosed with progressive metastatic Castration Resistant Prostate Cancer (CRPC). The purpose of this study is to compare the overall survival of patients with progressive metastatic CRPC treated with either a) enzalutamide only or b) enzalutamide with abiraterone and prednisone. Approximately 60 participants will take part in this study at the University of Iowa.
Clarine Halvorsen, 319-356-3944
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.